Vietnamese Balm for Colds, Fever, and Digestive Complaints

This is the plant's oldest and most prominent claim, and the honest starting point is that no human trial of any kind has ever tested it. What follows is what the tradition actually says, what genuinely new preclinical chemistry has emerged in the last two years, and where a marketing claim quietly borrows from a different plant entirely.

Table of Contents

  1. The Traditional Claim, Stated Precisely
  2. What "Summer-Heat with Dampness" Actually Describes
  3. Why Zero Human Trials Exist, and What That Does and Does Not Mean
  4. Herbs in the Same Category That Do Have Trials
  5. The New Preclinical Antiviral Leads (2025)
  6. The Digestive Angle: A Mouse Constipation Study
  7. The Formula-Substitution Trap: Two "Xiang-Ru" Drugs That May Not Contain This Plant
  8. Steam Inhalation: What It Is and Its One Real Hazard
  9. What an Actual Trial Would Have to Look Like
  10. Key Research Papers
  11. Connections

The Traditional Claim, Stated Precisely

Four related but distinct traditions converge on this plant for the same general purpose, and it is worth naming all four before treating them as one claim.

Notice what the tradition is not claiming. It is not a claim to cure influenza, to shorten a fever of unknown cause, or to treat serious infection. It is a claim about a specific, self-limiting seasonal syndrome, treated at home, for a few days. Modern marketing that stretches this into "antiviral" or "immune-boosting" language is doing something the tradition itself never did — a distinction also drawn correctly by the Houttuynia food-and-tradition page, whose "clears lung heat" retrofitted into "antiviral" is the identical move.

Back to Table of Contents

What "Summer-Heat with Dampness" Actually Describes

A modern reader meeting this phrase cold has no way to parse it, so it is worth translating plainly rather than leaving it as decorative old-medicine language.

The setting: a hot, humid climate — the plant's native range and its traditional use both concentrate in monsoon Southeast and East Asia. The trigger: heavy outdoor exertion or heat exposure followed by a sudden temperature drop — cold food, cold drink, or stepping from a hot street into air conditioning. The presentation: chills without sweating, headache, a feeling of heaviness, abdominal fullness or bloating, nausea, and loose stools. A modern clinician would recognise this cluster as overlapping heat-exhaustion physiology, a viral prodrome, and mild food-borne gastroenteritis, three things that a pre-germ-theory medical system had no way to separate and folded into one seasonal category.

This matters for reading the rest of this page honestly. The traditional indication is not narrowly "fever" or narrowly "diarrhoea" — it is a whole-body seasonal syndrome, which is exactly why the plant's modern research base, described below, touches antiviral, anti-inflammatory and gastrointestinal endpoints without any of those three lines of research having been designed to test the traditional claim directly.

Back to Table of Contents

Why Zero Human Trials Exist, and What That Does and Does Not Mean

Absence of evidence is itself a finding here, and it deserves to be stated as one rather than glossed over. No randomised trial, no open-label trial, no case series, and no pharmacokinetic study of Elsholtzia ciliata in a human being has ever been published, for fever, for cold symptoms, for digestive complaints, or for anything else. This is not "evidence of no effect." It is the complete absence of anyone having looked.

Why has nobody looked? A few plausible, unglamorous reasons, none of which is a scientific objection to the plant itself:

What the absence does not mean is that the traditional use is therefore safe to treat as clinically proven, or that concentrated preparations inherit the same reassurance as the food-level exposure described on the main topic page. Those are two different questions, and this page is about the first one only.

Back to Table of Contents

Herbs in the Same Category That Do Have Trials

It is sometimes argued that traditional cold-and-flu herbs simply cannot be trialled, that the endpoints are too soft and the illness too variable. That argument does not survive contact with the actual literature on related plants, which is why naming the comparators matters more than any hedge.

The point of naming these is not to shame Vietnamese balm by comparison — it is to demonstrate that "you cannot trial a folk cold remedy" is false. Trials of exactly this kind, on culturally and botanically comparable plants, have been run. Nobody has yet run one on Elsholtzia ciliata, which is a fact about research funding and market size, not about whether the question is answerable.

Back to Table of Contents

The New Preclinical Antiviral Leads (2025)

Two papers published in 2025, both from cell-culture work, are the first modern findings that touch the traditional cold-and-flu claim even indirectly. Both are genuinely new, both are more specific and more rigorous than the older essential-oil screening work, and both are exactly what "preliminary" means — real results that stop well short of the traditional claim.

A human coronavirus, inhibited in a dish

A 2025 study grew an ethanol extract of Elsholtzia ciliata aerial parts against HCoV-OC43, a human betacoronavirus that causes ordinary common colds and is genetically related to SARS-CoV-2 — used here specifically as a safe BSL-2 laboratory stand-in for the pandemic virus. The crude extract reduced viral RNA, viral protein expression and plaque formation, with no measurable toxicity to the host cells up to 40 µg/mL. The researchers then isolated four individual compounds from the extract and found one, luteolin-7-O-glucoside, was substantially more potent than the crude extract on its own — an estimated IC50 near 2 µM (roughly 1 µg/mL) against 5 µg/mL for the whole extract.

Two things are worth stating plainly. First, this is real, specific, species-correct, recent work, not a borrowed citation from a different plant. Second, it is a cell-culture result. The authors' own paper says so directly: because the plant is traditionally taken as a tea, they propose oral administration as the next step "for further in vivo investigation" — meaning that step has not yet happened. No animal has been infected and treated with this extract; no person has taken it for a cold and been compared with a placebo group. A compound working against a virus in a dish is the first rung of a very long ladder, and antiviral drug development has a long history of promising cell-culture compounds that fail at the next rung for reasons of absorption, metabolism, or simply not reaching the right tissue at an achievable dose.

Inflammation, provoked by a virus mimic

A second 2025 paper, from a different but overlapping Korean research group, treated RAW264.7 macrophage cells with polyinosinic:polycytidylic acid (Poly I:C) — a synthetic double-stranded RNA that mimics what a cell "sees" during viral infection and triggers the same innate-immune alarm cascade a real virus would. Elsholtzia ciliata extract added to these cells reduced nitric oxide, iNOS, COX-2, and the pro-inflammatory signals PGE2, IL-1β, TNF-α, IFN-β, and IL-6, and dampened the intracellular signalling (AKT, TBK1/IRF3, MAPK, NF-κB) that drives those outputs. The paper's own background section states plainly that the plant is used traditionally for "antiviral, antibacterial, antipyretic, diaphoretic, carminative, astringent, and diuretic effects" — independent modern confirmation, from a horticultural-research institute rather than a marketing source, of exactly the traditional indication list given above.

This is a real anti-inflammatory finding in a viral-mimetic model, and it is the closest thing yet to a mechanistic bridge between the traditional "reduces the misery of a cold" claim and a laboratory measurement. It is still a dish of cells, not a sick person, and inflammation suppressed in a culture well does not automatically mean a shorter or milder illness in a body with an actual immune system, a liver metabolising the compound, and a real viral load to fight.

Back to Table of Contents

The Digestive Angle: A Mouse Constipation Study

The "summer-heat with dampness" syndrome, described above, includes gastrointestinal symptoms as a core part of the traditional picture, not an afterthought — which makes a 2025 Chinese mouse study the first modern data to touch that half of the claim.

Researchers screening edible traditional Chinese medicines for laxative activity tested an aqueous extract of Elsholtzia ciliata — the water-based preparation that actually matches how the herb is traditionally taken, unlike the essential-oil work described on the cardiovascular pharmacology page — in mice with loperamide-induced constipation, alongside a parallel extract of Hovenia dulcis (raisin tree). Both extracts significantly improved fecal volume and water content, reduced colonic tissue damage, increased expression of proteins associated with intestinal peristalsis (c-Kit, SCF) and gut-barrier integrity (ZO-1, occludin, claudin-1), and shifted gut bacterial populations toward butyrate-producing genera. The proposed mechanism is that increased butyrate production reduces inflammation and improves both barrier function and beneficial bacterial abundance.

This is a real, single-agent (not combined-formula) finding using an animal model and a preparation method that matches tradition, which makes it more directly relevant than most of the chemistry described elsewhere on these pages. It is still a mouse model of a specific type of drug-induced constipation, not a study of the "abdominal fullness and diarrhoea" picture that Chinese medicine actually describes for summer-heat illness — loperamide-induced constipation and diarrhoea sit at opposite ends of gut motility, so this paper tests a related but not identical question to the traditional indication. No human digestive study of any kind exists.

Back to Table of Contents

The Formula-Substitution Trap: Two "Xiang-Ru" Drugs That May Not Contain This Plant

Two Chinese studies report genuinely impressive results against H1N1 influenza in mice using formulas named after xiang ru, and both need to be read with real caution before either is credited to Vietnamese balm.

Both results are real, both are peer-reviewed, and both are exactly the kind of citation that must be labelled at the point of use rather than folded silently into "Vietnamese balm fights flu in mice." Three reasons:

  1. These are multi-herb formulas, not the single plant. Xiang ru is one ingredient among several in each decoction — the classical Xiang Ru Yin pattern traditionally combines it with white lentil and magnolia bark, as noted above. A formula's effect cannot be attributed to any one component without testing that component alone, and neither of these papers did.
  2. The species problem cuts directly through this formula tradition. A 2024 chemical-authentication study states plainly that the pharmacopoeial xiang ru — Mosla chinensis and its cultivar Jiangxiangru — has "increasingly been substituted by various species within the genera Elsholtzia and Mosla" because the plants are difficult to tell apart morphologically, and the authors had to develop mass-spectrometry chemical markers specifically to distinguish authentic xiang ru from the confusable Elsholtzia species growing alongside it. Neither influenza paper above reports which species, or which authentication method, went into its formula.
  3. Even if the formula's xiang ru component were confirmed as Elsholtzia ciliata, a multi-herb decoction result still would not establish what the single herb does alone — the same formula-substitution logic that applies to Triphala and haritaki, or to Trikatu and long pepper, applies here without modification.

The honest summary: two real animal studies show a xiang ru-named formula helping mice survive H1N1 lung injury. Neither tells you what a cup of kinh giới tea does, and neither can even confirm which plant was actually in the pot.

Back to Table of Contents

Steam Inhalation: What It Is and Its One Real Hazard

The xông — fresh or dried herb steeped in a bowl of just-boiled water, inhaled under a towel — is the most common Vietnamese household response to a cold, and it deserves a plain description rather than either dismissal or endorsement.

Mechanistically, this is an aromatic steam treatment: warm, humidified air carrying volatile plant compounds, inhaled directly. Warm humidified air itself has a long, unremarkable history of symptomatic comfort for nasal congestion, independent of what is dissolved in the water — which means any benefit felt is difficult to attribute specifically to the herb rather than to the steam. No study has isolated the herb's contribution from the steam's.

The one real, well-documented hazard is scalding, not the plant. A bowl of freshly boiled water held close to the face, under a towel, with reduced visibility, is a genuine burn risk — for a fidgeting child leaning too far in, or for anyone with reduced sensation or reduced mobility. This is a hazard of the method, present with any steam inhalation regardless of what herb is used, and it should be supervised accordingly rather than treated as a Vietnamese-balm-specific concern.

Back to Table of Contents

What an Actual Trial Would Have to Look Like

Naming the missing study precisely is a stronger move than a generic "more research is needed," because it demonstrates the question is answerable and simply has not been asked. A real trial of Vietnamese balm for the traditional cold-and-summer-heat indication would need:

Every element on this list is standard, feasible clinical-trial methodology, used routinely for other botanicals. None of it has been applied here. That is a statement about priorities and funding, not about whether the underlying question could be answered.

Back to Table of Contents

Key Research Papers

Every citation below was checked live against the PubMed record before being written into this page, using species-locked, title/abstract-scoped search terms rather than a bare genus name — Elsholtzia is a large genus with several traditionally conflated species, so a generic search risks pulling in E. splendens, E. bodinieri, E. rugulosa or Mosla chinensis results that describe a different plant entirely.

  1. Wang F, et al. Elsholtzia ciliata (Thunb.) Hyland: A Review of Phytochemistry and Pharmacology. Molecules. 2022. Catalogues 352 identified compounds and states plainly that this species' pharmacological activities include antiviral, antipyretic and analgesic effects among many others, alongside the confusion of medicinal sources described throughout these pages. PubMed search.
  2. Kim JH, et al. Anti-inflammatory effects of Elsholtzia ciliata extract on Poly I:C-treated RAW264.7 cells. Journal of Ethnopharmacology. 2025. The viral-RNA-mimetic macrophage study; also documents the traditional indication list (antiviral, antibacterial, antipyretic, diaphoretic, carminative, astringent, diuretic) in its own background section. PubMed search.
  3. Lee S, et al. Luteolin-7-O-glucoside from Elsholtzia ciliata extract inhibits the replication of coronavirus. PLoS One. 2025. The HCoV-OC43 finding, in vitro only. PubMed search.
  4. Wu J, et al. Aqueous extracts of Elsholtzia ciliata and Hovenia dulcis ameliorate loperamide-induced constipation in mice by promoting intestinal peristalsis and barrier function and the abundance of intestinal beneficial bacteria. Frontiers in Microbiology. 2025. PubMed search.
  5. Li Q, et al. Xin-Jia-Xiang-Ru-Yin alleviated H1N1-induced acute lung injury and inhibited the IFN-γ-related regulatory pathway in summer flu. Biomedicine & Pharmacotherapy. 2018. A multi-herb formula, not the single plant — see the formula-substitution discussion above. PubMed search.
  6. Wu QF, et al. Anti-H1N1 influenza effects and its possible mechanism of Huanglian Xiangru Decoction. Journal of Ethnopharmacology. 2016. Also a formula, from the classical monograph Book of Nanyang for Life Saving. PubMed search.
  7. Zeng Z, et al. Rapid characterization of non-volatile phenolic compounds reveals the reliable chemical markers for authentication of traditional Chinese medicine Xiang-ru among confusing Elsholtzia species. Chinese Journal of Natural Medicines. 2024. The species-substitution problem behind the formula trap, documented directly. PubMed search.
  8. Melchior J, et al. Controlled trial of standardized Andrographis paniculata extract (SHA-10) in reducing the symptoms of common cold, using visual-analogue symptom scoring. Randomised, double-blind, placebo-controlled. The comparator-herb methodology this page's plant has never had applied to it. PubMed search.
  9. Andrographis extract (AP-Bio / KalmCold), Phase III randomised placebo-controlled trial in uncomplicated upper respiratory viral infection (common cold). 2023. A second, more recent Andrographis RCT, underscoring how routine this trial design is for a comparably obscure Asian traditional cold herb. PubMed search.
  10. Timmer A, et al. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Cochrane-adjacent methodology. The evidentiary bar this page's plant has not yet approached. PubMed search.

Back to Table of Contents

Connections

Back to Table of Contents